Poseida Therapeutics
2023 Annual Meeting

Investor Materials

View online versions of our 2023 Annual Meeting Materials.

You may request paper copies of the investor materials online now, by email or by phone by dialing 866-648-8133.

Annual_Report

Annual Report

Proxy_Statement

Proxy Statement

Vote Online

Vote Now

Your vote is important! Vote your proxy online now or by phone by dialing 866-859-1992.

Annual Meeting Details

Date:
June 15, 2023

Virtual Meeting:

REGISTER HERE 

Deadline to Register*
June 13, 2023
8:00 p.m. Pacific Time

Time:
1:00 p.m. Pacific Time

*Note: You must register by the deadline above to be eligible to participate in the meeting.

About Us

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company’s approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients.

Powered by Donnelley Financial Solutions.
Copyright © Mediant Communications Inc. All Rights Reserved.